Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Sees Large Decrease in Short Interest

Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) saw a significant drop in short interest in the month of January. As of January 15th, there was short interest totaling 135,611 shares, a drop of 57.8% from the December 31st total of 321,082 shares. Based on an average trading volume of 82,847 shares, the days-to-cover ratio is currently 1.6 days. Currently, 0.4% of the company’s shares are sold short. Currently, 0.4% of the company’s shares are sold short. Based on an average trading volume of 82,847 shares, the days-to-cover ratio is currently 1.6 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Adlai Nortye in a research report on Wednesday, January 21st. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Reduce”.

Adlai Nortye Stock Performance

ANL opened at $6.53 on Friday. Adlai Nortye has a 52 week low of $0.88 and a 52 week high of $6.53. The business has a 50 day moving average of $1.73 and a 200-day moving average of $1.66.

About Adlai Nortye

Adlai Nortye Inc (NASDAQ: ANL) is a specialty chemical manufacturer headquartered in China’s Jiangsu Province. The company focuses on the research, development, production and sale of fine chemicals, with a primary emphasis on amino acids and their derivatives.

Adlai Nortye’s product portfolio includes betaine compounds, a range of high-purity L-amino acids such as L-methionine, L-threonine and glycine, as well as various chemical intermediates. These offerings serve multiple end markets, including animal feed and nutrition, personal care and cosmetic formulations, pharmaceutical ingredients and industrial chemical processes.

The company operates multiple production facilities alongside an in-house research and development center dedicated to process innovation and quality control.